EuroBiotech: More Articles of Note


> European biotechs raised $2.3 billion in the first half of the year, BioWorld reports. That puts fundraising in 2017 well ahead of last year at the halfway point but some way short of the bumper 2015. Public markets drove the bounce back. Private equity funding fell year on year. BioWorld

> GlaxoSmithKline selected the third target in its collaboration with Immunocore. The collaborators are going after cancer targets that cannot be hit by antibody-based drugs. Statement

> ProQR picked up orphan drug designations for QRX-411 on both sides of the Atlantic. The EMA and FDA designations cover the use of the drug in the treatment of retinitis pigmentosa. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> eTheRNA Immunotherapies moved its mRNA based cancer immunotherapy into the clinic. The phase 1b trial is assessing the candidate in patients who have had metastatic melanoma removed surgically. Statement   

> Galapagos and Gilead started another clinical trial of filgotinib. The phase 2 study is testing the JAK1 inhibitor in patients with noninfectious uveitis. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.